Radioimmunotherapy With Tositumomab and Iodine-131 Tositumomab for Low-Grade Non-Hodgkin Lymphoma: Nursing Implications

Judith M. Estes

Kathleen J. Clapp

ONF 2004, 31(6), 1119-1126. DOI: 10.1188/04.ONF.1119-1126

Purpose/Objectives: To review radioimmunotherapy approaches for low-grade non-Hodgkin lymphoma (NHL) with a focus on tositumomab and iodine-131 tositumomab (Bexxar®, Corixa Corporation, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA). Nursing implications for Bexxar therapy are reviewed, including radiation safety, patient education, and the management of therapy-related toxicities.

Jump to a section

    References

    American Cancer Society. (2004). Cancer facts and figures 2004. Atlanta, GA: Author.

    Appelbaum, F.R., Sullivan, K.M., Buckner, C.D., Clift, R.A., Deeg, H.J., Fefer, A., et al. (1987). Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology, 5, 1340-1347.

    Bruner, D.W., Bucholtz, J.D., Iwamoto, R., & Strohl, R. (Eds.). (1998). Manual for radiation oncology nursing practice and education. Pittsburgh, PA: Oncology Nursing Society.

    Corixa Corporation. (2003). Bexxar® [Package insert]. Retrieved September 27, 2004, from http://www.corixa.com/bexxar/bexxarpackageinsert.pdf

    Dunne-Daly, C.F. (1999). Principles of radiotherapy and radiobiology. Seminars in Oncology Nursing, 15, 250-259.

    Grillo-Lopez, A., Chinn, P.C., & Morena, R.A. (1995). Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD-20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma [Abstract]. Blood, 86, 55a.

    Harris, N.L., Jaffe, E.S, Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., et al. (1994). A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.

    Hendrix, C.S., de Leon, C., & Dillman, R.O. (2002). Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Clinical Journal of Oncology Nursing, 6, 144-148.

    Horning, S.J., Lucas, J.B., Younes, A., Podoloff, D., Jain, V., Kroll, S., et al. (2000). Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multi-center phase II study [Abstract]. Blood, 96(11, Pt. 1), 508a.

    Kaminski, M.S., Estes, J., Tuck, M., Mann, J., Jr., Fisher, S., Kison, P., et al. (2000). Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL) [Abstract]. Proceedings of the American Society for Clinical Oncology, 19, 5a.

    Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000). Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 96, 1259-1266.

    Kaminski, M.S., Zasadny, K.R., Francis, I.R., Fenner, M.C., Ross, C.W., Milik, A.W., et al. (1996). Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology, 14, 1974-1981.

    Kaminski, M.S., Zasadny, K.R., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993). Radioimmunotherapy of B-cell lymphoma with [131]anti-B1 (anti-CD-20) antibody. New England Journal of Medicine, 329, 459-465.

    Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Seonard, J., Fehrenbacher, L., et al. (2001). Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 19, 3908-3911.

    Kwak, L.W., Grossbard, M.L., & Urba, W.J. (1995). Clinical applications of monoclonal antibodies in cancer. In V.T. DeVita, S. Hellman, & S.A. Rosenberg (Eds.), Biologic therapy of cancer (2nd ed., pp. 553-565). Philadelphia: Lippincott.

    Leonard, J., Coleman, M., Kostakoglu, L., Morris, A., Gregory, S., Link, B., et al. (2001). Bexxar™ (iodine I-131 tositumomab and tositumomab) can be administered safely in sequential combination with chemotherapy in initial treatment of non-Hodgkin's lymphoma (NHL) [Abstract]. Proceedings of the American Society for Clinical Oncology, 20, 287a.

    McDonald, R., & Takahashi, G. (1999, June). Practical considerations for iodine I 131 tositumomab. Paper presented at Nuclear Medicine and Oncology: A Therapeutic Partnership for the Treatment of Non-Hodgkin's Lymphoma Symposium, Los Angeles, CA.

    McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Czuczman, M.S., Williams, M.E., Hayman, M.R., et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.

    Meredith, R.F., & LoBuglio, A.F. (1997). Recent progress in radioimmunotherapy for cancer. Oncology, 11, 979-984.

    Nuclear Regulatory Commission. (1997). The code of federal regulation: Title 10-Energy. Retrieved September 7, 2001, from http://www.nrc.gov/NCR/CFR/FRONT/title10.html

    Press, W.O. (2000). Physics for practitioners: The use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma. Seminars in Hematology, 37(4, Suppl. 7), 2-8.

    Rosenthal, D.S., & Eyre, H.J. (1995). Hodgkin's disease and non-Hodgkin's lymphomas. In G.P. Murphy, W. Lawrence, & R.E. Lenhard (Eds.), American Cancer Society textbook of clinical oncology (2nd ed., pp. 451-469). Atlanta, GA: American Cancer Society.

    Rutar, F.J., Augustine, S.C., Colcher, D., Siegel, J.A., Jacobson, D.A., Tempero, M.A., et al. (2001). Outpatient treatment with (131) I-anti-B1 antibody: Radiation exposure to family members. Journal of Nuclear Medicine, 42, 907-915.

    Siegel, J.A., Kroll, S., Regan, D., Kaminski, M., & Wahl, R.L. (2002). A practical methodology for patient release after tositumomab and I-131 tositumomab therapy. Journal of Nuclear Medicine, 43, 354-363.

    Stashenko, P., Nadler, L.M., Hardy, R., & Schlossman, S.F. (1980). Characterization of a human B lymphocyte-specific antigen. Journal of Immunology, 125, 1678-1685.

    Tizard, I.R. (1992). Immunology: An introduction (3rd ed.). New York: Saunders.

    Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., et al. (2000). Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 18, 1316-1323.

    Wahl, R.L., Zasadny, K.R., MacFarlane, D., Francis, I.R., Ross, C.W., Estes, J., et al. (1998). Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase I experience. Journal of Nuclear Medicine, 39(8, Suppl.), 21S-27S.

    Wilder, R.B., DeNardo, G.L., & DeNardo, S.J. (1996). Radioimmunotherapy: Recent results and future directions. Journal of Clinical Oncology, 14, 1383-1400.

    Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuzman, M.S., Emmanouilides, C., Joyce, R., et al. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 2453-2463.

    Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., et al. (1999). Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3793-3803.